Assertio (ASRT)
(Delayed Data from NSDQ)
$1.16 USD
+0.03 (2.65%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.16 USD
+0.03 (2.65%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
Zacks News
Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $2.23 in the latest trading session, marking a +1.36% move from the prior day.
Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Assertio Holdings' (ASRT) Q1 earnings call, investors will focus on the sales performance of its marketed products.
INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate
by Zacks Equity Research
INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Histogen Inc (HSTO) have performed compared to their sector so far this year.
Actinium (ATNM) Up on Commercialization Deal With Immedica
by Zacks Equity Research
Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.
Best Value Stocks to Buy for April 13th
by Zacks Equity Research
WFG, GOGL, and ASRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 13, 2022.
Aerie (AERI) Expands Market Presence Despite Stiff Competition
by Zacks Equity Research
Aerie (AERI) is progressing well with the development of its ophthalmology pipeline. Its partnership with Santen Pharmaceuticals allows it to expand the presence of its drugs outside the United States.
4 Reasons to Add Novo Nordisk (NVO) Stock to Your Portfolio
by Zacks Equity Research
Novo Nordisk's (NVO) portfolio of marketed drugs are driving year over year growth. The company has one of the broadest diabetes portfolios in the industry.
BioCryst (BCRX) Pauses Enrolment in Key Studies, Stock Down
by Zacks Equity Research
BCX9930 is a BioCryst Pharmaceuticals' (BCRX) oral Factor D inhibitor being evaluated in several studies for the treatment of complement-mediated diseases
JAZZ Inks Deal With Werewolf to Add Oncology Candidate
by Zacks Equity Research
Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.
PTC Therapeutics (PTCT) Soars 11.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks.com featured highlights Assertio Holdings, VAALCO Energy and DLH Holdings
by Zacks Equity Research
Assertio Holdings, VAALCO Energy and DLH Holdings have been highlighted in this Screen of the Week article.
3 Top Breakout Stocks to Invest In for Solid Returns
by Tirthankar Chakraborty
Assertio Holdings, Inc. (ASRT), VAALCO Energy, Inc. (EGY) and DLH Holdings Corp. (DLHC) have been selected as the breakout stocks for today.
Axsome (AXSM) to Acquire Jazz's Sleep Disorder Drug, Sunosi
by Zacks Equity Research
Axsome (AXSM) inks an agreement with Jazz Pharmaceuticals to acquire the latter's new sleep disorder drug, Sunosi. The transaction is expected to close in the second quarter of 2022.
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
JAZZ Initiates Zepzelca Basket Study in Advanced Solid Tumors
by Zacks Equity Research
JAZZ enrolls the first patient in a mid-stage study to evaluate its lung cancer drug, Zepzelca, in advanced and difficult-to-treat cancer indications in previously-treated patients.
New Strong Buy Stocks for March 24th
by Zacks Equity Research
ASRT, CPRI, GRIN, OCDX, and KN have been added to the Zacks Rank #1 (Strong Buy) List on March 24, 2022.
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Buy Stocks for March 15th
by Zacks Equity Research
CPRI, GOGL, EOG, ASRT, and IMO have been added to the Zacks Rank #1 (Strong Buy) List on March 15, 2022.
The Zacks Analyst Blog Highlights USA Truck, TimkenSteel, JAKKS Pacific, United Fire Group, and Assertio Holdings
by Zacks Equity Research
USA Truck, TimkenSteel, JAKKS Pacific, United Fire Group, and Assertio Holdings are included in today's Analyst blog.
Bayer (BAYRY) to Divest a Business Unit to Cinven for $2.6B
by Zacks Equity Research
Bayer (BAYRY) to sell off its Environmental Science Professional business unit to Cinven for $2.6 billion. The company plans to focus on core agricultural businesses.
Allogene's (ALLO) CAR T Therapy Gets Fast Track Designation
by Zacks Equity Research
The FDA grants a Fast Track designation to Allogene's (ALLO) early-stage CAR T therapy candidate, ALLO-316, for treating advanced or metastatic clear cell RCC.
Top 5 High-Flying Small Hidden Gems Amid Wall Street Mayhem
by Nalak Das
We have narrowed our search to five small-cap stocks that have provided double-digit returns year to date. These are: USAK, TMST, JAKK, UFCS and ASRT.
Bayer (BAYRY) Files for Nubeqa's Label Expansion in US & EU
by Zacks Equity Research
Bayer (BAYRY) submits regulatory applications to the FDA and the EMA, seeking approval for a new indication of Nubeqa for treating metastatic hormone-sensitive prostate cancer.
Is Liquidia Technologies, Inc. (LQDA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.